The Cardinal Conundrum: When Growth Meets Valuation Woes Jim Cramer's recent endorsement of Cardinal Health has sent shockwaves through the healthcare sector. Beneath the surface, however, lies a more complex story.
The company's ability to adapt and grow in a rapidly changing industry is undeniable, yet its valuation woes raise concerns about the sustainability of this momentum.
Cardinal's shift towards specialty pharmaceuticals and higher margin healthcare services has been remarkable.